Sagimet Biosciences Inc. (SGMT) Stock Score, Valuation & Financial Research

Sagimet Biosciences Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for SGMT

Sagimet Biosciences Inc. does not currently have a complete Wall Street Score. The stored market price is USD 8.76. These figures are a research snapshot, not a buy or sell recommendation.

What Sagimet Biosciences Inc. does

Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic and fibrotic pathways in the United States. The company’s lead drug candidate is Denifanstat, an oral, once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction-associated steatohepatitis, acne, and select forms of cancer. It also develops TVB-3567, a FASN inhibitor for the treatment of acne indication; and other oncology programs, such as solid tumor and glioblastoma. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

Sagimet Biosciences is a clinical-stage biopharmaceutical company that does not currently generate revenue from product sales. Its business model relies on research and development of FASN inhibitors, funded through capital raises and potential future licensing or collaboration agreements.

Products and services

  • The company is developing denifanstat, a selective fatty acid synthase (FASN) inhibitor, for the treatment of metabolic and fibrotic diseases such as MASH.

Customer types

Healthcare providers and patients (potential future).

Suppliers, materials and equipment

  • Contract Manufacturing Organizations (CMOs) — The company relies on third-party contract manufacturers for the production of drug substance and drug product for clinical trials; specific supplier names are not disclosed. Source

Business relationships and partnerships

  • Ascletis Pharma Inc. — A licensing agreement granting Ascletis exclusive rights to develop and commercialize denifanstat in Greater China. Source

Competitors and product-market comparisons

  • Madrigal Pharmaceuticals, Inc. — Competes in the development of therapies for MASH and other metabolic liver diseases. Source
  • Viking Therapeutics, Inc. — Competes in the development of therapies for MASH and other metabolic liver diseases. Source

Business strengths to evaluate

  • Proprietary FASN inhibitor platform Source

Business risks and research considerations

  • History of operating losses and expectation of future losses Source
  • Dependence on third-party manufacturers for clinical supply Source

Sources: Company research source

Company research refreshed 2026-10-12. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

SGMT financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 8.76
Market capitalization:
285.42M (currency not supplied)
Revenue:
USD 0.00
Net income:
USD -47.08M
Free cash flow:
USD -45.65M
Cash:
USD 165.9M
Total debt:
USD 1.94M
EPS:
USD -1.28

What stands out

  • Free cash flow is USD -45.65M, negative for the stored period.
  • The balance sheet shows USD 165.9M of cash versus USD 1.94M of total debt, an excess of cash over debt on these two reported measures.
  • The current research record carries a fundamental change risk warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Cash exceeds debt by USD 163.96M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for SGMT

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can SGMT fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • How is SGMT likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
  • What specifically needs to improve for SGMT to reach sustainable profitability?
  • What does the current fundamental change risk warning mean for the reliability or interpretation of SGMT's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-01.

Research-input completeness: 73% of the scoring inputs required for this public page are currently available.

How to research SGMT

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.